Edgewise Therapeutics (EWTX) News Today $22.80 -0.57 (-2.44%) Closing price 04:00 PM EasternExtended Trading$22.82 +0.02 (+0.09%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Truist Financial Keeps Their Buy Rating on Edgewise Therapeutics (EWTX)March 24 at 6:10 PM | markets.businessinsider.comIntech Investment Management LLC Buys 14,944 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Intech Investment Management LLC increased its stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 75.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,844 shares of the company's stock afterMarch 24 at 4:06 AM | marketbeat.comTruist maintains Buy rating on Edgewise Therapeutics stockMarch 23 at 4:27 AM | uk.investing.comVictory Capital Management Inc. Purchases Shares of 21,568 Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Victory Capital Management Inc. acquired a new stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 21,568 shares of the company's stock, valued at approximately $5March 22 at 3:16 AM | marketbeat.comEWTX Makes Notable Cross Below Critical Moving AverageMarch 21, 2025 | nasdaq.comPiper Sandler Sticks to Its Buy Rating for Edgewise Therapeutics (EWTX)March 21, 2025 | markets.businessinsider.comCharles Schwab Investment Management Inc. Purchases 15,273 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Charles Schwab Investment Management Inc. grew its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 2.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 537,359 shares of the company'sMarch 21, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Down 3.5% - Should You Sell?Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 3.5% - Time to Sell?March 20, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - Time to Sell?Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - Time to Sell?March 18, 2025 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Position Lifted by AmundiAmundi raised its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 127.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 341,687 shares of the company's stock after purchasing an additional 191,267 shares during the period. Amundi owned 0.36%March 15, 2025 | marketbeat.comEdgewise Therapeutics (EWTX) Gets a Buy from WedbushMarch 13, 2025 | markets.businessinsider.comEdgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.3% - Time to Sell?Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.3% - What's Next?March 13, 2025 | marketbeat.comEdgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific ConferenceMarch 11, 2025 | finance.yahoo.comEdgewise Therapeutics: More Expensive Now, But Much More DeriskedMarch 10, 2025 | seekingalpha.comRBC Capital Sticks to Its Buy Rating for Edgewise Therapeutics (EWTX)March 10, 2025 | markets.businessinsider.comScotiabank Initiates Coverage of Edgewise Therapeutics (EWTX) with Sector Outperform RecommendationMarch 8, 2025 | msn.comEdgewise Therapeutics Target of Unusually High Options Trading (NASDAQ:EWTX)Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) saw unusually large options trading on Friday. Investors acquired 2,157 call options on the stock. This is an increase of approximately 170% compared to the average volume of 800 call options.March 8, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Earns Sector Outperform Rating from Analysts at ScotiabankScotiabank began coverage on shares of Edgewise Therapeutics in a research note on Friday. They issued a "sector outperform" rating and a $50.00 price target on the stock.March 8, 2025 | marketbeat.comCandriam S.C.A. Lowers Stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Candriam S.C.A. reduced its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 13.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 253,965 shares of the company's stock after selling 40,659 shares during the period. CandriMarch 8, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Up 4.9% - Time to Buy?Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 4.9% - Still a Buy?March 7, 2025 | marketbeat.comEdgewise Therapeutics initiated with an Outperform at ScotiabankMarch 7, 2025 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Edgewise Therapeutics (EWTX) and Walgreens Boots Alliance (WBA)March 7, 2025 | markets.businessinsider.comWhat is Wedbush's Forecast for EWTX FY2026 Earnings?Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) - Investment analysts at Wedbush reduced their FY2026 earnings estimates for Edgewise Therapeutics in a note issued to investors on Monday, March 3rd. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($2.25) perMarch 7, 2025 | marketbeat.comLeerink Partnrs Issues Negative Outlook for EWTX EarningsEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) - Equities researchers at Leerink Partnrs lowered their Q1 2025 EPS estimates for Edgewise Therapeutics in a research note issued on Monday, March 3rd. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings ofMarch 6, 2025 | marketbeat.comRoyal Bank of Canada Reiterates Outperform Rating for Edgewise Therapeutics (NASDAQ:EWTX)Royal Bank of Canada reaffirmed an "outperform" rating and set a $56.00 target price on shares of Edgewise Therapeutics in a research note on Tuesday.March 5, 2025 | marketbeat.comEdgewise Therapeutics (EWTX) Gets a Buy from RBC CapitalMarch 4, 2025 | markets.businessinsider.comEdgewise Therapeutics reports Q4 EPS (42c), consensus (42c)March 3, 2025 | markets.businessinsider.comEdgewise Therapeutics (NASDAQ:EWTX) Releases Earnings Results, Misses Estimates By $0.03 EPSEdgewise Therapeutics (NASDAQ:EWTX - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.03).March 3, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPSEdgewise Therapeutics (NASDAQ:EWTX - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.03).March 3, 2025 | marketbeat.comHandelsbanken Fonder AB Acquires Shares of 21,800 Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Handelsbanken Fonder AB acquired a new stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 21,800 shares of the company's stock, valued at apMarch 2, 2025 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Rating of "Moderate Buy" from AnalystsEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. TheMarch 2, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Up 5.9% - Here's WhyEdgewise Therapeutics (NASDAQ:EWTX) Shares Up 5.9% - Time to Buy?February 21, 2025 | marketbeat.comEdgewise Therapeutics (EWTX) to Release Earnings on ThursdayEdgewise Therapeutics (NASDAQ:EWTX) will be releasing earnings before the market opens on Thursday, February 27.February 20, 2025 | marketbeat.comShould You Invest in Edgewise Therapeutics (EWTX)?February 19, 2025 | msn.com10,316 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Acquired by AlphaCentric Advisors LLCAlphaCentric Advisors LLC bought a new position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 10,316 shares of the company's stock, valued at approximately $275,000. Several othFebruary 17, 2025 | marketbeat.comdgewise Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorganFebruary 14, 2025 | markets.businessinsider.comJPMorgan lifts Edgewise Therapeutics target to $45February 14, 2025 | msn.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by abrdn plcabrdn plc cut its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 30.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 178,043 shares of the company's stock after selling 78,602 shares duringFebruary 10, 2025 | marketbeat.comEdgewise Therapeutics chief business officer sells $300,300 in stockFebruary 8, 2025 | msn.comEdgewise Therapeutics chief scientific officer sells $276,776 in stockFebruary 8, 2025 | msn.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Alan J. Russell Sells 1,200 SharesFebruary 8, 2025 | insidertrades.comInsider Selling: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Sells 1,200 Shares of StockEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) insider Alan J. Russell sold 1,200 shares of the firm's stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $30.13, for a total value of $36,156.00. Following the transaction, the insider now owns 14,863 shares in the company, valued at approximately $447,822.19. This trade represents a 7.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.February 7, 2025 | marketbeat.comInsider Selling: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CEO Sells 8,636 Shares of StockEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CEO Kevin Koch sold 8,636 shares of the company's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $30.03, for a total value of $259,339.08. Following the completion of the sale, the chief executive officer now owns 14,478 shares of the company's stock, valued at $434,774.34. This represents a 37.36 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.February 7, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Down 7.1% - Here's WhyEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 7.1% - What's Next?February 7, 2025 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of "Moderate Buy" by AnalystsEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buyFebruary 5, 2025 | marketbeat.comEdgewise Therapeutics, Inc. (NASDAQ:EWTX) Short Interest UpdateEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 6,140,000 shares, an increase of 8.9% from the December 31st total of 5,640,000 shares. Approximately 9.8% of the shares of the stock are sold short. Based on an average daily volume of 837,700 shares, the days-to-cover ratio is presently 7.3 days.February 2, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Up - What's Next?Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Up - Here's WhyJanuary 31, 2025 | marketbeat.comJoanne M. Donovan Sells 25,000 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) StockEdgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne M. Donovan sold 25,000 shares of the company's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $27.63, for a total transaction of $690,750.00. Following the completion of the sale, the chief marketing officer now directly owns 16,358 shares of the company's stock, valued at approximately $451,971.54. This trade represents a 60.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.January 30, 2025 | marketbeat.comMoody Aldrich Partners LLC Acquires 36,775 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX)Moody Aldrich Partners LLC boosted its stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 24.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 187,January 29, 2025 | marketbeat.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Price Up 7.1% - Time to Buy?Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Up 7.1% - Time to Buy?January 24, 2025 | marketbeat.com Remove Ads Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address EWTX Media Mentions By Week EWTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EWTX News Sentiment▼0.740.68▲Average Medical News Sentiment EWTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EWTX Articles This Week▼84▲EWTX Articles Average Week Remove Ads Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sarepta Therapeutics News Today Vaxcyte News Today Qiagen News Today Roivant Sciences News Today Revolution Medicines News Today Lantheus News Today Legend Biotech News Today TG Therapeutics News Today BridgeBio Pharma News Today Axsome Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EWTX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EWTX Stock Free EWTX Stock Alerts